ArticleReproduction & fertility2026
A pilot study on the use of transcutaneous auricular vagus nerve stimulation to relieve dysmenorrhea in patients with adenomyosis and endometriosis.
Article in Reproduction & fertility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenomyosis and endometriosis are two sister diseases that cause menstrual pain and other symptoms. We have previously reported that patients with these conditions have a less active 'calm-and-rest' system and a more active 'stress-and-alert' system. Other studies have shown that a gentle, non-invasive treatment called transcutaneous auricular vagus nerve stimulation (taVNS) can safely and effectively boost the 'calm-and-rest' system in many disorders. So we wanted to see if taVNS could also help with menstrual pain caused by endometriosis and adenomyosis. We tried it in a small pilot study with four patients with adenomyosis and two patients with endometriosis. They received taVNS for six months. We found that taVNS was well tolerated and relieved their pain three and six months after taVNS. These early results are encouraging, but because the study was small, we need larger, more rigorous studies to fully know how well taVNS works for this kind of pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.